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The effects, costs and savings of neonatal screening for Cysfic 
Fibrosis 
E. Van den Akker van Mar ie  1, H.M. Dankett 1,P. Vet ker k 1, J.E. Danker t Rcelse 9 
~TNO Prevention arm Health, Leiden, 2Department of Pediatrics, Pediatric 
Pulrrmr~logy, Amsterdam, the NetherlarMs 
The goal of neonatal screening for Cystic Fibrosis is to start therapeutic 
interventions as early in l ife as possible. By early intervention, organ damage can 
be prevented or postponed for as long as possible. The potential to inform parents 
about genetic risks before a next preguancy is another benefit of newborn screening 
for CF. As a result, the prevalence of offspring bom with CF wil l  be reduced as 
compared with a situation without CF screening. 
Currently, neonatal screening for CF is implemented in several countries. In The 
Netherlands however, introduction of neonatal screening for CF is still under 
debate. 
Aim A review of the effects, costs and savings of newbom screening for CF in The 
Netherlands to provide information in the decision prccess of including neonatal 
screening for CF in the current newborn screening program. 
Methods The required information was collected by the use of cl inical information, 
a systematic review of the literature and expert opinions. The costs of screening and 
accompanying diagnostic prccedures were est imated in circumstances with 
screening and circumstances without screening. Also, the savings generated by 
parents with a child with CF deciding not to have another child, were included. 
Sensitivity analyses, varying the values of several assumptions, are cmlent ly 
executed. 
Results The study wi l l  be completed by March 2CO5 and data can be presented at 
the conference. 
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Sweat testing equipment compared: the Nanoduct versus the 
Macroduct 
J.E. Danker t Roelse, I. Bon 
VU Medical Centre, Dept Pediatrics, Pediatric Pulmmu)logy, Amsterdam, the 
Netherlaruls 
The Macroduct system ad the semi quantitat ive measurement of sweat 
conductivity is general ly considered as a reliable screening instrument for sweat 
testing 1. However, ha small infants the Macroduct often fails to induce sufficient 
amounts of sweat for analysis. According to the manufacturer the Nanoduct can 
perform a rel iable analysis of electrolytes in sweat in minimal ly 3 ~tl sweat. 
A im.  To assess the performance of the Nanoduct for sweat esting. 
Pat ients and  methods. Sweat tests by means of the Macroduct and the Nanoduct 
were carried out simultaneously ha 13 patients with CF, age 1.6 20.2 yrs, and in 
22 controls, age 6 days 12.7 yrs. Then chloride concentrations of the collected 
sweat samples in the Macr oduct coil system were determined according to standard 
prccedures. Sweat tests with semi quantitative values of > 50 were considered 
positive. Bivariate Pearson's r was calculated for coiielations. 
Results. The Nanoduct was successful at the first attempt in all subjects, whi le  the 
Macroduct had to be repeated in 7 (20%). The results of the Nanoduct highly 
correlated (r 0,969) wi th the quantitative chemical analyses. For both the 
Macroduct and the Nanoduct a sensitivity of 100% was observed. Positive 
predictive values were 100% for the Nanoduct, and 75% for the Macroduct. 
Conclusion. The Nanoduct seems to be a reliable instrument for sweat testing. It's 
use might be considered in excluding or confirming CF in newborns with a positive 
screening test for CF. 
Reference. I. Le Grys E4. J Pediatrics I996, 892-7. 
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Validation of a new line probe assay for the amplification and 
simultaneous detection of 21 Italian CFTR mutaf ions 
C. Van Loon, J. Van Crombruggen, I. Azzuz, L. Celis, M. B liiser, L. Timmer oans, 
G. Verpooten 
Innogenetics NV, Gent, Belgium 
The performance of INNO LiPA CFTR I tal ian Regional for the detection of 21 
Italian CFTR mutations and their wi ld type sequences was validated ha house. A 
total of 85 anonymous whole blood samples, originating from different countries, 
was amplified, 84 of which where analyzed with the regional strip. 
For these samples a concordance of 96.4% (81/84; 95% CI [89.9%; 99.3%]) with 
conventional genotyping methods was observed after initial testing, with 100% 
(84/84; 95% CI [95.7%; 100%]) concordance after discrepancy testing of tbree 
samples. Upon initial testing, INNO LiFA CFTR Ital ian Regional detected mutation 
$549R A>C (tested three times) in two samples, and mutation G1244E (tested 
three times) in another sample. Sequencing of all three samples confirmed the result 
obtained with INNO LiPA CFTR I tal ian Regional. 
Development of the assay has aimed at avoiding reactivity with other than the 
specified mutations or polymotphisms in the CFTR gene. The eight different 
mutations/polymorphisms encountered in this study did not show any cross 
reactivity with the probes present on the strip. 
DNA extracted from ten buccal brush samples and twenty dried blood spots from 
healthy blood donors was also successfully genotyped. 
ha conclusion, this study showed that the INNO LiFA CFTR Ital ian Regional is a 
rel iable and accurate test for the detection of 21 Ital ian CF related mutations i  the 
CFTR gene region. 
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Guidelines for announcing the diagnosis of cystic fibrosis after 
neonatal screening 
S. Ravil ly 1, L. Gu6gant on 2 and the working group of "Vaincr e la Mucoviscidose" 
ll&inere la Mucoviscidose, Paris, 2Centre de Perharidy, Roscoff 
Introduct ion:  The French CF Association "Vaincre la Mucoviscidose" has for 
many years promoted neonatal screening. Decided en 2CO2 by the French Health 
Authorities, every region in France has implemented CF neonatal screening under 
the responsibility of the screening program Association (AFDPHE). Screened 
babies are referred to ne of the 30 pediatric accredited CF centre. The conditions 
of disclosure of the diagnostic and the initial contact between the CF centre and the 
parents are determinant to establish a confident relationship involving parents as 
real partners of care. 
A ims:  A working group met to discuss optimal announcement procedures for a 
disease like CF, in this particular pre symptomatic context, in order to minimize as 
much as possible parental stress, to obtain the best quality of c are and to avoid may 
perturbation ha the child's emotional development and the family stability. 
Methods:  After a large literature search, a working group (7 paediatricians, 1 
specialized nurse, 1 physiotherapist, 1 social worker, 2 psychologists and 2 parents) 
elaborated guidelines. The document has been validated by paediatricians from the 
medical council of "Vaincre la Mucoviscidose" and by 14 parents. This brcchure 
was published mad addressed to every CF team. 
Results:  The guidelines are divided in f ive themes: who should announce; with 
whom can the announcement bemade; to whom should the announcement bemade; 
how must the announcement be made; what should be announced. Guidelines are 
adapted to the results of the tests: IRT, genetic testing, sweat est. 
Conclusions: Beyond valorising the results of this work, the next two steps wi l l  be 
to set up information tools for parents and families, mad to evaluate the impact of 
these guidelines upon parents and health care providers. 
